Jan 5 2011
OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.
The patent (U.S. Pat. No. US 7,803,183) covers a coating on an implantable medical device that has one or more layers of a matrix. Incorporated into the matrix are antibodies or antibody fragments that allow for capture in vivo of circulating EPCs.
"This patent further expands OrbusNeich's unique intellectual property portfolio of the Genous technology," said Robert Cottone, vice president of intellectual property and technologies at OrbusNeich. "We are continuing to develop our pro-healing technology for our next generation stent platform, which combines both luminal cell capture with abluminal drug elution and is currently in clinical trial evaluation."
Study highlights how age affects nasal cell response to SARS-CoV-2